Inhaled Insulin Treatment Delayed

Last week's announcement about a proposed inhaled diabetes treatment appears to be a bit pre mature.MannKind Corporation said the FDA has delayed Afrezza's  release for three months.

The agency said it needs more time to find out what the long-term side effects are.

Last week, an FDA advisory panel recommended Afrezza's approval.